A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Shanghai East Hospital in Solid Tumors, Adult. SEO and diligence focus: LCAR-C18S cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Solid Tumors, Adult
Modality: protein therapy
Target: LCAR-C18S cells
Sponsor: Shanghai East Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: LCAR-C18S cells
View original source fields
Condition raw: Solid Tumors, Adult
Condition normalized: Solid Tumors, Adult
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: LCAR-C18S cells
Target normalized: LCAR-C18S cells